RESEARCH LETTER

Performance of Serum β2-Microglobulin– and β-Trace Protein–Based Panel Markers and 2021 Creatinine- and Cystatin-Based GFR Estimating Equations in Pakistan

To the Editor:

Estimating glomerular filtration rate (GFR) using the creatinine-based equation (eGFRcr) as an initial test and the cystatin C–based equations (eGFRcys or eGFRcr-cys) as a confirmatory test is recommended.1 Because 2009 CKD-EPI (Chronic Kidney Disease Epidemiology Collaboration) eGFRcr and 2012 CKD-EPI eGFRcr-cys included a term for race, which is a social and not biological construct, and these equations overestimated eGFR in Black individuals, the equations were refitted in 2021 without the term for Black race in the United States. The new 2021 CKD-EPI eGFRcr-cys equation was more accurate than the new equations without race with either creatinine or cystatin alone in both Black and non-Black individuals.2 β2-Microglobulin (B2M) and β-trace protein (BTP), alternate filtration markers less influenced by race, are being considered for use in a panel including cystatin C (3-marker) or creatinine and cystatin C (4-marker).3 Previously we reported that 2009 eGFRcr overestimated measured GFR (mGFR) in an adult population in Pakistan and that the calibrated equation CKD-EPI eGFRcr-PK eliminated bias and improved accuracy.4 We also showed that, unlike its performance in other populations,5 2012 CKD-EPI eGFRcys exhibited substantial bias in Pakistanis and that 2012 eGFRcr-cys was no better than eGFRcr-PK.6

In this study, we aimed to evaluate the performance of the 3- and 4-marker B2M and BTP panels, 2021 CKD-EPI eGFRcr, and 2021 CKD-EPI eGFRcr-cys. The primary reference comparator was CKD-EPI eGFRcr-PK, which is currently used in Pakistan. We also explored factors other than GFR that influence B2M and BTP levels.

In a cross-sectional study, B2M and BTP were measured among 557 Pakistani participants (≥40 years; 49.7% men). mGFR was calculated using urinary inulin clearance.5 A detailed description of the study methods is provided in Item S1, and a study flowchart is provided in Figure S1.

We compared bias (median difference in mGFR and eGFR), precision (interquartile range of differences), and accuracy (percentage of eGFR within 30% of mGFR and root mean square logarithmic [base e] error) between mGFR and eGFR. We used linear regression models to assess the associations between non-GFR determinants and log-transformed (base e) B2M and BTP, adjusting for mGFR and mGFR measurement error (±2.5%, Table 1). The strength of significant associations was defined as intermediate and strong if the absolute percentage difference in B2M or BTP levels was 5%-10% and >10%, respectively.

For the 557 participants, the mean (standard deviation) age was 51 (10) years. The median value (interquartile range) of mGFR was 91 (74-110) mL/min/1.73 m². As shown in Table 2, both the 3- and 4-marker BTM and B2P panels exhibited a large positive bias and did not improve precision or accuracy (both P > 0.05) relative to eGFRcr-PK. The 3- and 4-marker panels exacerbated bias (P < 0.001) and did not improve precision or accuracy over 2012 eGFRcys or 2012 eGFRcr-cys. 2021 eGFRcr and eGFRcr-cys did not improve precision or accuracy over eGFRcr-PK. Results remained consistent when stratified by eGFR level (Tables S1 and S2).

In Table 1, non-GFR determinants with intermediate and strong associations with higher BTP included male sex, history of heart disease, and lower waist circumference. Determinants of higher B2M included male sex, higher total body fat, and lower serum albumin. Except for sex, determinants associated with cystatin C and creatinine differed from those of BTP and B2M.

These results suggest that neither the 3- nor 4-marker B2M and BTP panels, nor the race-free 2021 eGFRcr or 2021 eGFRcr-cys equations, were better than eGFRcr-PK. The 3- and 4-marker panels did not improve the performance of 2012 eGFRcys and eGFRcr-cys. We also observed that non-GFR determinants of BTP and B2M differed from those of cystatin C and creatinine. History of heart disease had a strong and intermediate association with higher BTP and cystatin C, respectively, but not with B2M or creatinine. Higher albumin levels were intermediately associated with lower BTP and B2M, but not with cystatin C or creatinine. To date, the 3- and 4-marker panels have been assessed predominantly among Europid and US Black populations.3 Other eGFR equations containing BTP and B2M were assessed in Europid, Black, and Chinese populations with inconsistent performance compared with eGFRcr-cys.9,10 The 3-marker BTM and B2P panel was more accurate than the 2012 eGFRcys, but not the 2012 eGFRcr-cys, and the 4-marker BTM and B2P panel was comparable to 2012 eGFRcr-cys.3

Previously, we observed that 2012 eGFRcys exhibited a large bias in the Pakistani population.6 Unlike our decision to modify 2009 eGFRcr to account for the bias, presumably due to the lower muscle mass and protein intake in Pakistani compared with Europid populations in which 2009 eGFRcr was developed, we elected not to calibrate 2012 eGFRcys in Pakistan because the source of bias was unknown and because of the uncertainty of the calibrated equation robustness across the country.7 The usefulness of B2M and BTP in improving eGFR in Pakistan remains limited. Future studies are needed to validate our findings in South Asia and the South Asian diaspora elsewhere to explore unidentified non-GFR determinants of cystatin C, B2M, and BTP and to evaluate the feasibility of modifying these equations to improve GFR estimation. Additional research should include cost-effectiveness analyses of filtration markers other than creatinine for broad applications, especially for low-resource countries.
Table 1. General Linear Model Analysis of IQR-Standardized mGFR and Non-GFR Determinants on Natural Log-Transformed (Base e) Filtration Markers (N = 557)

| eGFR Determinants of Interest | IQR | Mean Percent Change |
|-------------------------------|-----|---------------------|
|                               | B2M (95% CI) | BTP (95% CI) | Cystatin C (95% CI) | Creatinine (95% CI) |
| Measured GFR (mGFR)           | 36.6 (-478 (-51.1, -44.2)^2) | -52.4 (-55.5, -49.0)^b | -42.6 (-45.1, -40.0)^b | -50.0 (-53.0, -46.9)^b |
| Age (year)                    | 13.0 (0.002 (-3.67, 3.82) | 3.56 (-2.63, 10.2) | 3.02 (-0.14, 6.30) | -1.00 (-4.41, 2.52) |
| Sex (men vs women)            | -10.1 (2.33, 17.2) | 20.7 (9.22, 30.8) | 13.1 (7.07, 18.7)^b | 24.8 (17.8, 31.2)^b |
| Smoking (yes vs no)           | -5.0 (-0.36, 10.7) | 4.91 (-3.61, 14.2) | 5.14 (0.72, 9.74)^b | -0.66 (-5.37, 4.28) |
| Body mass index (kg/m²)       | 6.6 (0.63 (-4.35, 5.88) | 7.10 (-0.98, 15.8) | 4.49 (0.36, 8.80) | 12.4 (7.03, 18.1)^b |
| Waist circumference (cm)      | 15.0 (0.12 (-4.04, 4.46) | -7.39 (-13.2, -1.10)^b | 0.35 (-2.88, 3.69) | -3.07 (-6.98, 1.01) |
| Total body fat (kg)           | 10.6 (6.40 (3.70, 9.18)^b | 3.81 (0.22, 7.52)^b | 2.65 (0.67, 4.67)^b | -0.19 (-2.93, 2.62)^b |
| Lean body mass (kg)           | 14.7 (2.55 (-1.46, 6.73) | -1.43 (-7.17, 4.67) | 1.08 (-2.05, 4.31) | 7.33 (2.71, 12.1)^b |
| History of heart disease (yes vs no) | 7.25 (-1.13, 16.3) | 11.6 (1.64, 22.5)^b | 8.32 (3.16, 14.6)^b | 6.62 (-0.42, 14.2) |
| Serum albumin (g/dL)          | 0.4 (-7.39 (-9.84, -4.88)^b | -6.49 (-10.1, -2.69)^b | -3.93 (-6.05, -1.77)^b | -0.60 (-2.85, 1.71) |
| LDL cholesterol (mmol/L)      | 37.0 (-3.61 (-6.06, -1.10)^b | -2.25 (-5.98, 1.63) | -2.10 (-4.14, -0.02)^b | -1.22 (-3.63, 1.36) |
| Dietary protein intake (g/day) | 19.0 (0.39 (-0.34, 1.14) | 0.18 (-0.49, 0.85) | 0.27 (-0.05, 0.59) | -0.25 (-0.90, 0.41) |
| Urine creatinine (mg/kg/d)    | 6.4 (-1.82 (-10.2, 7.43) | 9.90 (-4.72, 26.8) | 0.67 (-5.47, 7.21) | 17.5 (8.11, 27.2)^b |

R² for the multivariable model with mGFR measurement error
- B2M: 78.2%
- BTP: 64.2%
- Cystatin C: 81.4%
- Creatinine: 80.5%

R² for mGFR with mGFR measurement error
- B2M: 74.6%
- BTP: 59.5%
- Cystatin C: 75.3%
- Creatinine: 65.4%

R² for mGFR without mGFR measurement error
- B2M: 73.4%
- BTP: 58.5%
- Cystatin C: 74.2%
- Creatinine: 64.4%

Note: Mean percent change in serum B2M, BTP, cystatin C, and creatinine levels for an IQR-standardized increment in an eGFR determinant variable, calculated as 100 × (eβ-coefficient – 1) using error-in-variables regression models assuming log-transformed mGFR with ±2.5% measurement error. The general linear model included all variables presented in the table and corrected for mGFR measurement error. Strength of association for statistically significant results is indicated as follows: 
- strong (absolute average percent difference in B2M/BTP levels >10%).
- intermediate (absolute average percent difference in B2M/BTP levels 5–10% inclusive).
- weak (absolute average percent difference in B2M/BTP levels <5%). The same code was applied for cystatin C and creatinine. R² was based on all eGFR determinants presented in the table.

SUPPLEMENTARY MATERIAL

Supplementary File 1 (PDF)
Figure S1: Flowchart of the study design.
Item S1: Detailed description of methods.
Table S1: Linear Regression Between Baseline Characteristics and Log-Transformed BTP and B2M Adjusting for Age, Sex, and Measured GFR (N = 557)
Table S2: Linear Regression Between Baseline Characteristics and Log-Transformed B2M and BTP Adjusting for All Non-GFR Determinants and Measured GFR (N = 557)

ARTICLE INFORMATION

Authors’ Affiliations: Program in Health Services and Systems Research, Duke-NUS Medical School, Singapore (YW, THJ); Department of Nutrition, Harvard T.H. Chan School of Public Health, Boston, MA (YW); Division of Nephrology, Department of Medicine, Tufts Medical Center, Boston, MA (ASL, LAI); Department of Community Health Sciences, Aga Khan University, Karachi, Pakistan (SJ); Division of Women & Child Health, Aga Khan University, Karachi, Pakistan (RB); Department of Medicine, Aga Khan University, Karachi, Pakistan (ZS, SY, THJ); Department of Laboratory Medicine and Pathology, University of Minnesota Medical School, Minneapolis, MN (ABK); Center for Quantitative Medicine, Office of Clinical Sciences, Duke-NUS Medical School, Singapore (JCA); Department of Renal Medicine, Singapore General Hospital, Singapore (THJ); and Duke Global Health Institute, Duke University, Durham, NC (THJ).

Address for Correspondence: Tazeen H. Jafar, Program in Health Services and Systems Research, Duke-NUS Medical School, 8 College Road, 169857, Singapore. Email: tazeen.jafar@duke-nus.edu.sg

Authors’ Contributions: Research idea and study design: THJ, ASL, LAI; data acquisition: THJ, SJ, RB, SY, ZS; data analysis: YW, JA, ABK, THJ; interpretation and first draft: YW with input from THJ; critical revisions and approval of final paper: all authors. Each author contributed important intellectual content during manuscript drafting or revision and accepts accountability for the overall work by ensuring that questions pertaining to the accuracy or integrity of any portion of the work are appropriately investigated and resolved.

Support: The study was supported by a research award (1R03TW007588-01A1) from the National Institutes of Health, Fogarty International Center (PI: THJ). The measurements and analyses were supported by grants from the National Institute of Diabetes and Digestive and Kidney Diseases grant R01DK097020 “Estimating GFR from a Panel of Endogenous Filtration Markers” to Tufts Medical Center. YW is supported by the National Research Service Award training-grant from the National Institutes of Health (T32HL098048). The design, conduct, analysis,
interpretation, and presentation of the data were the responsibility of the authors with no involvement from the funders.

**Financial Disclosure:** The authors declare that they have no relevant financial interests.

**Peer Review:** Received June 27, 2021 Evaluated by 1 external peer reviewer and a statistician with editorial input from an Acting Editor-in-Chief (Editorial Board Member Mehmet Kanbay, MD). Accepted in revised form January 17, 2022. The involvement of an Acting Editor-in-Chief to handle the peer-review and decision-making processes was to comply with Kidney Medicine’s procedures for potential conflicts of interest for editors, described in the Information for Authors & Journal Policies.

**Publication Information:** © 2022 The Authors. Published by Elsevier Inc. on behalf of the National Kidney Foundation, Inc. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/). with doi 10.1016/j.xkme.2022.100444

**REFERENCES**

1. Summary of recommendation statements. Kidney Int Suppl (2011). 2013;3(1):s-14.
2. Inker LA, Eneanya ND, Coresh J, et al. New creatinine- and cystatin C-based equations to estimate GFR without race. *N Engl J Med*. 2021;385(19):1737-1749. doi:10.1056/NEJMoA2102953
3. Inker LA, Couture SJ, Tighiouart H, et al. A new panel-estimated GFR, including β₂-microglobulin and β-trace protein and not including race, developed in a diverse population. *Am J Kidney Dis*. 2021;77(5):671-683.
4. Jessani S, Levey AS, Bux R, et al. Estimation of GFR in South Asians: a study from the general population in Pakistan. *Am J Kidney Dis*. 2014;63(1):49-58.
5. Inker LA, Schmid CH, Tighiouart H, et al. Estimating glomerular filtration rate from serum creatinine and cystatin C. *N Engl J Med*. 2012;367(1):20-29.
6. Wang Y, Levey AS, Inker LA, et al. Performance and determinants of serum creatinine and cystatin C–based GFR estimating equations in South Asians. *Kidney Int Rep*. 2021;6(4):962-975.
7. Jafar TH, Islam M, Jessani S, et al. Level and determinants of serum creatinine and cystatin C-based GFR estimation equations in South Asians. *Kidney Int*. 2011;78(5):764-772.
8. Rolin HA III, Hall PM, Wei R. Inaccuracy of estimated creatinine clearance for prediction of iothalamate glomerular filtration rate. *Am J Kidney Dis*. 1984;4(1):48-54.
9. Inker LA, Tighiouart H, Coresh J, et al. GFR estimation using β-trace protein and β2-microglobulin in CKD. *Am J Kidney Dis*. 2016;67(1):40-48.
10. Chen N, Shi H, Zhang L, et al. GFR estimation using a panel of filtration markers in Shanghai and Beijing. *Kidney Med*. 2020;2(2):172-180.